PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS
申请人:Inflazome Limited
公开号:US20210332020A1
公开(公告)日:2021-10-28
The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyclic group, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted at the 2- and 4-positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP
3
inhibition.
US9120774B2
申请人:——
公开号:US9120774B2
公开(公告)日:2015-09-01
[EN] NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES<br/>[FR] ANALOGUES DE NOVOBIOCINE COMPORTANT DES GROUPES FONCTIONNELS GLUCIDIQUES MODIFIÉS
申请人:UNIV KANSAS
公开号:WO2010096650A1
公开(公告)日:2010-08-26
The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.